Cupid Ltd. Raises FY27 Guidance to ₹800+ Cr Revenue, ₹250+ Cr Profit on Strong Q2
Cupid Limited expects Q2 FY27 revenue to exceed ₹200 crore, raising FY27 guidance to ₹800+ crore revenue and ₹250+ crore net profit. Key updates include warrant conversion, in-principle approval for a South African manufacturing venture, and a USD 5 million follow-on investment in a healthcare partnership. The company is also enhancing its FMCG distribution and operationalizing its Palava facility.
The significant upward revision in revenue and profit guidance, along with strategic expansion initiatives like the South African venture and increased investment in partnerships, are expected to have a substantial impact on the company's future performance.
The company has raised its revenue and profit guidance for FY27 and reported strong operational highlights, indicating positive business momentum.
Cupid Limited has announced a strong business update for the second quarter of Fiscal Year 2027 (Q2 FY27), with total revenue expected to surpass ₹200 crore.
Driven by sustained momentum in key business verticals and improved market visibility, the company has revised its full-year FY27 guidance upwards. The revised revenue guidance is now ₹800+ crore, and the net profit guidance has been increased to ₹250+ crore. This upward revision is supported by anticipated continued growth through Q3 and Q4 FY27, progress in operationalizing the Palava facility, and expansion of its healthcare and personal care portfolio.
Key operational highlights for Q2 FY27 include the approval for converting up to 30 lakh warrants of Baazar Style Retail Limited into equity shares at ₹328.25 per share. Cupid also received in-principle approval for a manufacturing venture in South Africa, adopting an asset-light model to support local manufacturing and African market expansion. Furthermore, the company strengthened its strategic healthcare partnership with GII Health care Investment Limited through an additional USD 5 million follow-on investment. Cupid's market position has been bolstered by its inclusion in the BSE Group ‘A’, NIFTY Small Cap 250, and the FTSE Emerging Markets All Cap Index.
Looking ahead, Cupid plans to scale its domestic FMCG distribution, operationalize the Palava manufacturing facility, expand its healthcare and personal care portfolio with new products, and strengthen its international healthcare business. The company also aims to build regional manufacturing platforms, starting with the proposed South African venture, and explore strategic healthcare opportunities.
What to do with a filing like this
Cupid Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cupid Limited. Read the original for the full detail.